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Abstract: The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as 
allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-
lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant 
dual TORC1/2 inhibitor, in 56 lymphoma cell lines. We observed anti-tumor activity across 56 
lymphoma models with a median IC50 value of 250 nM after 72 h of exposure. PQR620 was largely 
cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. Both the single 
agent and the combination data were validated in xenograft models. The data support further 
evaluation of PQR620 as a single agent or in combination with venetoclax. 




The high frequency of genomic alterations in lymphomas affecting genes coding for proteins 
involved in the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
pathway [1,2] highlights the importance of this signaling cascade as a therapeutic target. mTOR is an 
atypical serine/threonine kinase that mediates a variety of signals that directly or indirectly regulate 
cellular growth and metabolism [3,4]. It is present in two complexes, mTOR complex 1 (TORC1) and 
mTOR complex 2 (TORC2), which differ for the presence of additional proteins. Acute exposure to 
rapamycin inhibits TORC1 but not TORC2. It is now recognized that not only TORC1 but also TORC2 
is positively regulated by the PI3K signaling [3,4]. Importantly, the first generation of mTOR 
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inhibitors, sirolimus (rapamycin), temsirolimus (CCI779), everolimus (RAD001) and ridaforolimus 
(AP23573/MK-8669), act as allosteric inhibitors blocking the interaction between mTOR and FBPK12 
resulting in inhibition of TORC1 only [3,4]. These compounds are also known as rapalogs since they 
are chemically derived from rapamycin and maintain the same mechanism of action [3,4]. Rapalogs 
have shown preclinical and clinical anti-lymphoma activity [3–6]. In particular, temsirolimus 
demonstrated a higher response rate and progression free survival than investigators’ treatment 
choices in relapsed or refractory mantle cell lymphoma [7,8] and was approved by the European 
Medicines Agency (EMA) for patient populations [6]. However, the clinical activity of first generation 
mTOR inhibitors remains relatively limited and their use comes with side effects, as also 
demonstrated in two recently reported phase III clinical trials. The result of Temsirolimus was that it 
was less active and more toxic than the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib [9] and the 
addition of everolimus after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone) did not improve the outcome of patients with newly diagnosed high-risk diffuse large B 
cell lymphoma (DLBCL) [10]. Biologically, the inability of rapalogs to inhibit TORC1 associated with 
the activation of pro-survival feedback loops are known limitations in the mechanism of action of 
these types of compounds [3,4]. One way to overcome these problems is the design of dual TORC1/2 
inhibitors that target the catalytic site of mTOR [3,4,11–13], thus blocking the enzyme independently 
from its interacting proteins. Second generation mTOR inhibitors have shown stronger preclinical 
anti-tumor activity than allosteric mTOR inhibitors [3,4,11–15]. Results of the first reported phase I 
studies support this approach [3,4,16–18], although the toxicity profile can still represent an 
important issue [19,20]. Here, we report the anti-tumor activity of the brain penetrant dual TORC1/2 
inhibitor PQR620 [13] as a single agent and in combination with venetoclax in lymphoma models. 
2. Results 
2.1. PQR620 Has In Vitro Anti-Lymphoma Activity 
The anti-tumor activity of the novel TORC1/2 inhibitor PQR620 was assessed in a large panel of 
cell lines (n = 56) derived from lymphomas. The compound showed potent anti-proliferative activity 
in most of the tested cell lines (Table 1), with a median IC50 of 249.53 nM (95% C.I., 221–294). The most 
sensitive subtype was mantle cell lymphoma (MCL) (p = 0.0232 among all human cell lines; p = 0.0552 
within B-cell lymphomas) (Table 2). Conversely, the ALK+ anaplastic large cell lymphomas 
(ALK+ALCL) were the least sensitive (p = 0.0095) (Table 2). When we focused on diffuse large B cell 
lymphomas (DLBCL), representing the largest group of cell lines, the presence of MYC or BCL2 or 
the cell of origin did not affect the response to PQR620. However, DLBCL cell lines bearing TP53 
inactivation were less sensitive than TP53 wild-type cells (300 nM (95% C.I., 242–364) vs. 136 nM (95% 
C.I., 74–233); p = 0.0007). The anti-tumor activity of PQR620 appeared mostly cytostatic. Apoptosis 
induction was only seen in 8/56 cell lines (14%: 95% C.I., 6–26%) without association with histotype, 
BCL2, MYC or TP53 status (Table 1). PQR620 was able to act both on the TORC1 and TORC2 
pathways. Immunoblotting of DLBCL cell lines exposed to PQR620 (2 µM, 24 h) showed reduction 
of p-p70 S6 (Thr389) and p-4e-BP1 (Thr37/46) levels, indicative of TORC1 inhibition, and of p-AKT 
(Ser 473), indicative of TORC2 inhibition (Figure 1). 
Table 1. Anti-tumor activity of PQR620 in lymphoma cell lines. The IC50 was calculated after 72 h of 
drug exposure. Apoptosis was defined by at least a 1.5-fold increase in signal activation with respect 
to controls. BCL2, MYC and TP53 status were defined as previously reported [21]. 
Cell Line Histology IC50 (nM) 
Apoptosis 
Induction 









267.38 no n.a. n.a. n.a. 
DB GCB-DLBCL 507.79 no 1 0  
DOHH2 GCB-DLBCL 144.03 no 1 1 0 
ESKO-L MZL 378.09 no n.a. 0 n.a. 
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FARAGE GCB-DLBCL 246.32 no 0 0 1 
FE-PD PTCL-NOS 261.14 no n.a. n.a. n.a. 
GRANTA519 MCL 296.25 no 0 0 1 
H9 CTCL 614.19 no n.a. n.a. n.a. 
HAIR-M MZL 332.6 no n.a. 0 n.a. 
HBL1 ABC-DLBCL 370.8 no n.a. 0 n.a. 
HC1 MZL 170.76 no n.a. 0 n.a. 
HH CTCL 128.83 no n.a. n.a. n.a. 
HUT-78 CTCL 1396.59 no n.a. n.a. n.a. 
JEKO1 MCL 234.54 no 0 0 1 
JVM2 MCL 131.66 no 0 0 0 
KARPAS1106-P PMBCL 322.89 yes n.a. 0 n.a. 
KARPAS1718 MZL 735.31 no n.a. 0 1 
KARPAS299 ALCL, ALK+ 425.69 no n.a. n.a. 1 
KARPAS422 GCB-DLBCL 150.77 no 1 0 1 
KI-JK ALCL, ALK+ 456.52 no n.a. n.a. n.a. 
L82 ALCL, ALK+ 364.12 no n.a. n.a. 1 
MAC1 ALCL, ALK- 233.13 no n.a. n.a. n.a. 
MAVER1 MCL 91.78 no n.a. 1 1 
MEC1 CLL 348.52 no n.a. 0 1 
MINO MCL 120.78 no n.a. 1 1 
OCI-LY-1 GCB-DLBCL 314.96 no 1 0 1 
OCI-LY-10 ABC-DLBCL 220.15 no 0 0 1 
OCI-LY-18 GCB-DLBCL 285.09 no 1 1 1 
OCI-LY-19 GCB-DLBCL 128.81 no 1 n.a. 0 
OCI-LY-3 ABC-DLBCL 127.2 no 0 0 0 
OCI-LY-7 GCB-DLBCL 107.01 no 0 1 1 
OCI-LY-8 GCB-DLBCL 210.4 no 1 1 1 
PCL12 CLL 109.21 no n.a. 0 n.a. 
PFEIFFER GCB-DLBCL 1069.2 no 1 0 1 
RCK8 GCB-DLBCL 5.05 yes n.a. 0 0 
REC1 MCL 80.53 no n.a. 0 1 
RI-1 ABC-DLBCL 346.24 no n.a. 1 1 
SP49 MCL 250 yes n.a. 0 n.a. 
SP53 MCL 149.61 no n.a. 0 n.a. 
SSK41 MZL 200.25 no n.a. 0 n.a. 
SU-DHL-1 ALCL, ALK+ 670.6 yes n.a. n.a. 1 
SU-DHL-10 GCB-DLBCL 186.81 no 1 1 1 
SU-DHL-16 GCB-DLBCL 249.06 no n.a. n.a. n.a. 
SU-DHL-2 ABC-DLBCL 320.52 no 0 0 n.a. 
SU-DHL-4 GCB-DLBCL 226.36 no 1 0 1 
SU-DHL-5 GCB-DLBCL 166.23 yes 0 0 n.a. 
SU-DHL-6 GCB-DLBCL 398.97 no 1 0 1 
SU-DHL-8 GCB-DLBCL 396.7 no 0 1 n.a. 
TMD8 ABC-DLBCL 161.29 yes n.a. 0 0 
TOLEDO GCB-DLBCL 349.22 yes 1 1 1 
U2932 ABC-DLBCL 239.77 yes 0 0 1 
UPN1 MCL 253.94 no n.a. 0 1 
VAL GCB-DLBCL 261.31 no 1 1 0 
VL51 MZL 215.97 no n.a. 0 n.a. 
WSU-DLCL2 GCB-DLBCL 264.18 no 1 0 1 
Z138 MCL 237.47 no n.a. 1 n.a. 
DLBCL, diffuse large B-cell lymphoma; ABC-DLBCL, activated B-cell like diffuse large B-cell 
lymphoma; GCB-DLBCL, germinal center B-cell type diffuse large B-cell lymphoma; MCL, mantle 
cell lymphoma; ALCL, ALK+, ALK positive anaplastic large cell lymphoma; MZL, marginal zone 
lymphoma; CTCL, cutaneous T cell lymphoma; CLL, chronic B-cell leukemia; cALCL, cutaneous 
anaplastic large cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; PTCL-NOS, 
peripheral T cell lymphoma, not otherwise specified; n.a. not available. 
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Table 2. Anti-tumor activity of PQR620 based on histology. 
Histology Median IC50 (nM) 95% Conf. Interval Number of Cell Lines 
ABC-DLBCL 230 88–354 8 
GCB-DLBCL 249 181–325 19 
Canine DLBCL 267 n.d. 1 
MCL 192 101–253 10 
MZL 274 174–700 6 
PMBCL 323 n.d. 1 
CLL 229 109–349 * 2 
ALCL, ALK+ 441 364–671 * 4 
CTCL 614 129–1370 * 3 
PTCL-NOS 261 n.d. 1 
cALCL, ALKneg 233 n.d. 1 
DLBCL, diffuse large B-cell lymphoma; ABC-DLBCL, activated B-cell like diffuse large B-cell 
lymphoma; GCB-DLBCL, germinal center B-cell type diffuse large B-cell lymphoma; MCL, mantle 
cell lymphoma; ALCL, ALK+, ALK positive anaplastic large cell lymphoma; MZL, marginal zone 
lymphoma; CTCL, cutaneous T cell lymphoma; CLL, chronic B-cell leukemia; cALCL, cutaneous 
anaplastic large cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; PTCL-NOS, 
peripheral T cell lymphoma, not otherwise specified. * Lower confidence limit held at minimum 
(maximum) of sample [22]. n.d., not determined. 
 
Figure 1. PQR620 affects TORC1/2 signaling pathways by downregulating p-AKT, p-p70 S6 and p-
4e-BP1 in most cell lines. Two ABC-DLBCL (TMD8, Ri-1) and three GCB-DLBCL (OCI-LY-1, SU-DHL-
6, DoHH2) cell lines were treated with PQR620 (2 µM, 24 h) or, as control, DMSO. 
2.2. PQR620 Has In Vivo Anti-Lymphoma Activity 
The observed in vitro anti-tumor activity of PQR620 was then evaluated in an in vivo model 
using the activated B-cell-like (ABC) DLBCL RI-1 cell line. Treatments with PQR620 (100 mg/kg dose 
per day, one a day for 7 days/week (Qdx7/w)) started with 100–150 mm3 tumors and were carried 
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out for 21 days. PQR620 determined a decrease of the tumor volumes in comparison with controls 
from day 12 (p < 0.05) (Figure 2). There was no toxicity observed (reported as body weight loss). 
 
Figure 2. Effects of PQR620 as a single agent in a xenograft model of ABC-DLBCL. NOD-Scid mice 
subcutaneously inoculated with RI-1 (15 × 106) cells were split into two groups respectively treated 
with PQR620 (50 mg/kg, 7 days/w, po, n = 8), and a control vehicle (n = 8). In each box-plot, the line in 
the middle of the box represents the median and the box extends from the 25th to the 75th percentile 
(interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ). 
PQR620 versus vehicle, D2, D12, D14, D16, D19, D21, p < 0.05. 
2.3. PQR620 Has In Vitro and In Vivo Synergism with the BCL2 Inhibitor Venetoclax 
Due to the low induction of apoptosis after PQR620 as a single agent, we assessed the 
combination of the dual TORC1/2 inhibitor and the BCL2 inhibitor venetoclax in four DLBCL cell 
lines. The combination was in vitro synergistic in terms of anti-proliferative effect, as shown by 
exposing the cell lines to increasing doses of PQR620 and venetoclax as single agents or in 
combination (Figure S1). The addition of venetoclax increased the cell death, as indicated by a higher 
percentage of cells in the subG0 phase, in all the cell lines but the RI-1 in which the BCL2-inhibitor as 
a single agent was already highly cytotoxic (Figure 3). 
Based on the in vitro data, the activity of PQR620 (100 mg/kg dose per day, Qdx7/w, 21 days) in 
combination with venetoclax (100 mg/kg, Qdx7/w) was evaluated in an in vivo model using the 
germinal center B-cell type (GCB)-DLBCL cell line SU-DHL-6, bearing the t(14;18) chromosomal 
translocation (Figure 4). PQR620 determined a 2-fold decrease of the tumor volumes in comparison 
with controls. The combination of PQR620 with venetoclax showed highly significant differences 
either versus control or single agents during all days of the experiment (D4, D7, D9, D11, D14; p < 
0.001), resulting in an eradication of the implanted tumors in the absence of toxicity. The 
treated/control ratio (T/C) was <10% and, according to the U.S. National Cancer Institute (NCI) rules, 
the drug combination is declared as very active [23]. 
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Figure 3. The combination of PQR620 and venetoclax are more in vitro cytotoxic than the single 
agents. Cell cycle distribution of four DLBCL cell lines (GCB: DOHH2, SU-DHL-6; ABC: TMD8, RI1) 
treated with two different concentrations of PQR620 (250 nM or 1 µM) and/or venetoclax. 
 
Figure 4. The combination of PQR620 and venetoclax have stronger in vivo anti-tumor activity than 
the single agents in a xenograft model of GCB-DLBCL. NOD-Scid mice subcutaneously inoculated 
with SU-DHL-6 (15 × 106) cells were split into four groups respectively treated with PQR620 (100 
mg/kg, Qdx7/w, po, n = 8), Venetoclax (100 mg/kg, Qdx7/w, a combination of PQR620 with venetoclax 
(n = 8) and control vehicle (n = 8). PQR620 versus vehicle, D4–D14, p < 0.01; PQR620+venetoclax versus 
vehicle, D2–D14, p < 0.01; PQR620+venetoclax versus PQR620, D2–D14, p < 0.01; PQR620+venetoclax 
versus venetoclax, D2–D14, p < 0.01. In each box-plot, the line in the middle of the box represents the 
median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers 
extend to the upper and lower adjacent values (i.e., ±1.5 IQ). 
3. Discussion 
PQR620 is a novel dual TORC1/2 inhibitor with higher affinity for the enzymatic catalytic 
domain than previously reported second-generation compounds, such as INK128, CC223 and 
AZD2014 [13]. Here, we have shown that PQR620 had anti-tumor activity across 56 lymphoma 
models with a median IC50 value of 250 nM after 72 h of exposure, lower than what is reported in 66 
cell lines derived from various solid tumors [13]. 
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PQR620 was largely cytostatic, as is the case for other mTOR inhibitors in lymphomas [24–26]. 
However, when we combined the dual TORC1/TORC2 inhibitor with the BCL2 inhibitor venetoclax 
we observed an in vitro increase in cell death. Importantly, the benefit of the combination was 
validated in vivo upon treating xenografts derived from a GCB-DLBCL cell line with eradication of 
the tumor cells. Our data are in agreement with results obtained with venetoclax in combination with 
the other dual TORC1/TORC2, INK128, in acute myeloid leukemia [27], as well as data reported in 
lymphoma models with the BCL2 inhibitor combined with the dual PI3K/mTOR inhibitor bimiralisib 
(PQR309) [28] or different PI3K inhibitors [29–32]. The effect appears to be mediated by 
downregulation of anti-apoptotic proteins (MCL1 or BCLXL) mediated by the inhibition of the 
PI3K/AKT/mTOR pathway [29,31,32]. So far, in the clinical setting, the addition of venetoclax to other 
drugs seems feasible with no additional major toxicities [33–35]. 
For novel compounds, it is useful to identify groups of patients that might benefit the most from 
the treatment. Genomics studies have identified DLBCL subgroups with a constitutively activated 
PI3K/mTOR pathway: GCB- and ABC-DLBCL, belonging to the B-cell receptor signaling cluster [36], 
with GCB-DLBCL mostly falling into the newly described EZB subtype by Schmitz et al. [2] or Cluster 
3 by Chapuy et al. [1]. Importantly, the available DLBCL cell lines recapitulate the genetic and 
biologic features of these clinical entities [32,36], and PQR620 was active in such models. These 
classifications should be incorporated in the next clinical trials exploring PQR620 or other members 
of the same class to identify the patients that benefit the most from the treatment. 
The anti-tumor activity of PQR620 was particularly high in the MCL cell lines. This observation 
is interesting, since MCL is the histotype in which first generation mTOR inhibitors have been mostly 
clinically developed [3,4,8,37,38] with the European Medicines Agency (EMA) approval of 
temsirolimus for patients with relapsed/refractory disease [6,8]. Additionally, although they could 
not be defined as resistant, two groups of lymphomas presented reduced sensitivity to PQR620. 
ALK+ALCL presented a lower sensitivity than the other cell lines. In this tumor, the 
PI3K/AKT/mTOR pathway is downstream of ALK and constitutively active [39], but its inhibition 
alone might not be enough to efficiently target the lymphoma cells [40,41]. 
The second group with decreased PQR620 sensitivity was represented by mutated DLBCL cell 
lines bearing an inactive TP53. The contribution of TP53 in the response to mTOR inhibitors is not 
defined, but it is certainly relevant in particular conditions [24,42,43]. Data obtained in Eµ-Myc mouse 
lymphomas treated with everolimus clearly show that the lack of TP53 is a mechanism of primary 
resistance to the rapalog [24], indicating the importance of a TP53-mediated component in the 
mechanism of action of this class of compounds in lymphomas. Referring again to the newly 
described DLBCL subtypes, patients belonging to Cluster 2 [1], enriched in TP53 mutations and 
deletions, do not represent the best target population for PQR620. 
PQR620 was designed starting from the dual PI3K/mTOR inhibitor bimiralisib (PQR309) [44,45], 
increasing the molecule affinity for mTOR while decreasing binding to PI3K [13]. Bimiralisib has 
preclinical [28] and early clinical anti-lymphoma activity [46] in primary central nervous system 
lymphoma (PCNSL) [47]. PQR620 retains the ability of bimiralisib [44] to pass the blood-brain barrier 
[13]. This is relevant as PQR620 was active in ABC DLBCL cell lines, and the most common type, 
PCNSL, which is an aggressive type of extranodal lymphoma, for which PI3K/mTOR inhibitors are 
an area of clinical research [48]. Our data also show that PQ620 maintained the anti-tumor activity of 
bimiralisib reported in a canine DLBCL model [49], indicating that dogs with spontaneous 
lymphomas might represent an effective pre-clinical animal model to test this compound as well. 
4. Materials and Methods 
4.1. In Vitro Experiments 
Established human cell lines were cultured as previously described [28] and their identity was 
authenticated by short tandem repeat (STR) DNA profiling (IDEXX BioResearch, Ludwigsburg, 
Germany). The status of BCL2, MYC and TP53 was defined as previously reported [28]. PQR620 was 
provided by PIQUR Therapeutics and dissolved in dimethyl sulphoxide (DMSO) to obtain a stock 
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concentration of 10 mM. Venetoclax was obtained from Selleckchem (Houston, TX, USA). Viability 
and caspase-3/7 activation were assessed with the ApoTox-Glo Assay (Promega, Madison, WI, USA), 
as previously reported [21]. Apoptosis was defined by at least a 1.5-fold increase in signal activation 
over controls [21] and it was calculated in our models at the concentration of 1500 nM of PQR620. 
The effect on cell proliferation, cell cycle analysis and protein extraction, separation and 
immunoblotting were done as previously described [28,50]. The following antibodies were used: 
AKT (CST 9272, Cell signaling Technology, Danvers, MA, USA), p-AKT (Ser 473) (CST 4060), p-p70 
S6K (Thr 389) (CST 9205), p70 S6K (CST 9202), p-4e-BP1 (Thr 37/46) (CST 9459), 4e-BP1 (CST 9452) 
anti-GAPDH (Ebioscence FF26A). Associations in two-way tables were tested for statistical 
significance using either the X2 test or Fisher’s exact test (two-tailed), as appropriate. Binomial exact 
95% confidence intervals (95% C.I.s) were calculated for median percentages. Differences in IC50 
values among lymphoma subtypes were calculated using the Wilcoxon rank-sum test. Statistical 
significance was defined by p values of 0.05 or less. The synergism of drug combination was 
calculated by using the Chou–Talalay Index, as previously done [28]. Statistical analyses were 
performed using Stata/SE 12.1 for Mac (Stata Corporation, College Station, TX, USA), and boxplots 
with GraphPad Prism v. 7.0d (GraphPad Software, La Jolla, CA, USA). 
4.2. In Vivo Experiments 
Xenograft experiments with the RI-1 and the SU-DHL-6 cell lines were performed using NOD-
Scid (NOD.CB17-Prkdcscid/NCrHsd) mice and analysed as previously described [28]. Mice 
maintenance and animal experiments were performed under the Guide of Animal Care and Use 
(NCR 2011) and under the Chinese National Standard (GB14925-2010) (Crown Bioscience Inc., 
Taicang City, China). These studies were part of two larger works assessing other agents; hence, the 
vehicle arm for the RI-1 xenograft and the vehicle and the venetoclax arms for the SU-DHL-6 
xenograft have been previously reported [28]. In vivo toxicity was evaluated by weighing the mice 3 
times per week. Tumor weight loss higher than 10% in one week was considered to be the main sign 
of toxicity due to the drug. Treated/control ratio (T/C) was calculated at the end of the study as 
follows: T/C = (median tumor volume in the treated group/median tumor volume in the vehicle 
control group) × 100. A × T/C ≤ 42% was declared active in agreement with NCI criteria [23]. 
5. Conclusions 
In conclusion, PQR620 showed in vitro and in vivo anti-tumor activity in lymphoma models as 
a single agent and in combination with venetoclax, supporting its further development. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Figure S1: PQR620 was 
additive/synergistic when combined with venetoclax. Distribution of Chou-Talalay Combination Index (C.I.) 
values obtained in four DLBCL cell lines treated with different concentrations of PQR620 in combination with 
venetoclax. Y-axis, C.I. (C.I. < 0.9, synergism ; 0.9 < C.I. < 1.1, additive effect). 
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